Journal of Cardiovascular Disease Research
Have we really demonstrated the safety of Ibrutinib on standard dose? Rethinking the dose of Ibrutinib in CLL
|
This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author. This is in accordance with the Budapest Open Access Initiative (BOAI) definition of open access.
The articles in Journal of Cardiovascular Disease Research are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc-sa/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. |
|
|
|
|
Copyright � 2022 Journal of Cardiovascular Disease Research All Rights Reserved. Subject to change without notice from or liability to Journal of Cardiovascular Disease Research.
For best results, please use Internet Explorer or Google Chrome POLICIES & JOURNAL LINKS
Author Login
Reviewer Login About Publisher Advertising Policy Author's Rights and Obligations Conflict of Interest Policy Copyright Information Digital Archiving & Preservation Policies Editorial Policies Peer Review Policy Editorial & Peer Review Process License Information Plagiarism Policy Privacy Policy Protection of Research Participants (Statement On Human And Animal Rights) Publication Ethics and Publication Malpractice Statement Corrections, Retractions & Expressions of Concern Self-Archiving Policies Statement of Informed Consent Terms of Use |
Contact InformationJournal of cardiovascular Disease Research,
|